Skip to main content

How do you manage neuropathy from chemo?

Medically reviewed by Kristianne Hannemann, PharmD. Last updated on May 27, 2025.

Official Answer by Drugs.com

Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent and often distressing side effect of cancer treatment that affects the nerves. Common symptoms of CIPN are numbness, tingling, burning pain, and muscle weakness, which often occur in the hands and feet. In this article, we will explore why CIPN happens, how long it lasts, and what can help relieve or reverse symptoms.

What Causes Neuropathy from Chemo?

Chemotherapy-induced neuropathy is primarily caused by the toxic effects of certain chemotherapy drugs on the peripheral nervous system. Agents such as platinum-based drugs (e.g., cisplatin, oxaliplatin), taxanes (e.g., paclitaxel, docetaxel), vinca alkaloids, bortezomib (Velcade), and thalidomide are most commonly associated with CIPN. These drugs can damage sensory, motor, and autonomic nerves, often by disrupting microtubules, mitochondrial function, or causing oxidative stress. These effects ultimately impair nerve signaling and health.

Symptoms of chemotherapy-induced peripheral neuropathy (CIPN) can appear at various times, depending on the specific chemotherapy agent and individual patient factors. Many patients develop CIPN within one month of starting chemotherapy, but others may not experience symptoms until later in treatment. In some cases, CIPN can worsen or persist in the weeks or months following the completion of chemotherapy, a phenomenon sometimes referred to as "coasting". The severity depends on drug type, dosage, and patient factors.

What Are the Symptoms of Chemo-Induced Neuropathy?

Symptoms of CIPN can vary in severity and presentation, but commonly include:

These symptoms can significantly impact quality of life and may require dose reductions or discontinuation of chemotherapy.

How Long Does Neuropathy from Chemo Last?

The duration of CIPN varies widely. For many patients, symptoms begin during treatment and may persist for months or even years after chemotherapy ends. For some patients, symptoms may last lifelong. Studies show that:

Early management may improve outcomes. It is important to tell your cancer care team right away if you notice any symptoms of nerve problems.

Can Neuropathy from Chemo Be Reversed?

While some patients experience partial or complete recovery after stopping chemotherapy, a significant proportion continue to have persistent symptoms. The likelihood of reversal depends on the chemotherapy agent, dose, duration, and individual patient factors. Although neuropathy may improve over time, about one-third of patients face chronic symptoms that do not fully resolve. There are currently no guaranteed methods to reverse CIPN, but ongoing research aims to develop more effective treatments.

Current treatments for CIPN may include:

How to Manage and Relieve Neuropathy Symptoms?

Currently, there are no proven strategies to prevent CIPN, but early detection and dose adjustment may help limit severity. Management of neuropathy symptoms may include a combination of treatments, including pharmacological approaches and lifestyle measures. Some ways you can relieve symptoms due to CIPN include:

Conclusion

Managing chemotherapy-induced neuropathy involves a combination of symptom relief, supportive care, and ongoing research into more effective treatments. While some patients recover, many experience long-term symptoms, making early recognition essential for improving quality of life. Notify your healthcare provider right away if you experience any signs or symptoms of neuropathy.

References
  1. American Cancer Society. 2025. Peripheral Neuropathy. Accessed on May 26, 2025 at https://www.cancer.org/cancer/managing-cancer/side-effects/pain/peripheral-neuropathy.html
  2. Burgess, J., et. al. 2021. Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment. Oncology and therapy, 9(2), 385–450. https://doi.org/10.1007/s40487-021-00168-y
  3. Desforges, A. D., et. al. 2022. Treatment and diagnosis of chemotherapy-induced peripheral neuropathy: An update. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 147, 112671. https://doi.org/10.1016/j.biopha.2022.112671
  4. Maihöfner, C.,et. al. 2021. Chemotherapy-induced peripheral neuropathy (CIPN): current therapies and topical treatment option with high-concentration capsaicin. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 29(8), 4223–4238. https://doi.org/10.1007/s00520-021-06042-x
  5. Oyekan, A. O., et. al. 2024. Prevalence and predictors of chemotherapy-induced peripheral neuropathy among female breast cancer patients undergoing chemotherapy in Lagos. Ecancermedicalscience, 18, 1791. https://doi.org/10.3332/ecancer.2024.1791
  6. Renting, L., et. al. 2024. Vitamin B6 status and chronic chemotherapy-induced peripheral neuropathy: a prospective cohort study among patients with non-metastatic colorectal cancer receiving oxaliplatin-based chemotherapy. In: BMJ Oncology. DOI: https://doi.org/10.1136/bmjonc-2024-000462
  7. Starobova, H., et. al. 2017. Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy. Frontiers in molecular neuroscience, 10, 174. https://doi.org/10.3389/fnmol.2017.00174
  8. Teng, C., et. al. 2022. "POLAR-izing" Findings From Trials of Neuroprotection for Oxaliplatin Neuropathy. JNCI cancer spectrum, 6(6), pkac076. https://doi.org/10.1093/jncics/pkac076
  9. Tsai, C. H., et. al. 2021. Integrated Medicine for Chemotherapy-Induced Peripheral Neuropathy. International journal of molecular sciences, 22(17), 9257. https://doi.org/10.3390/ijms22179257

See also:

Related medical questions

Related support groups